Jack F M Wetzels

Radboud University Medical Centre (Radboudumc), Nymegen, Gelderland, Netherlands

Are you Jack F M Wetzels?

Claim your profile

Publications (371)2021.23 Total impact

  • Jack F.M. Wetzels, Nicole C.A.J. van de Kar
    American Journal of Kidney Diseases 02/2015; · 5.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since the beginning of living donor kidney transplantation, physicians have expressed concern about the possibility that unilateral nephrectomy can be harmful to a healthy individual. To investigate if the elevated intra-abdominal pressure (IAP) during laparoscopic donor nephrectomy causes early damage to the remaining kidney we evaluated urine biomarkers after laparoscopic donor nephrectomy. We measured albumin and alpha-1-microglobulin (α-1-MGB) in urine samples collected during and after open and laparoscopic donor nephrectomy and laparoscopic cholecystectomy and colectomy. Additionally, kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were measured in urine samples collected during and after laparoscopic donor nephrectomy and colectomy. The same biomarkers were studied in patients randomly assigned to standard or low IAP during laparoscopic donor nephrectomy. We observed a peak in urinary albumin excretion during all procedures. Urine α-1-MGB rose in the post-operative period with a peak on the third postoperative day after donor nephrectomy. Urine α-1-MGB did not increase after laparoscopic cholecystectomy and colectomy. After laparoscopic nephrectomy we observed slight increases in urine KIM 1 during surgery and in urine NGAL at day 2-3 after the procedure. After laparoscopic colectomy both KIM-1, and NGAL were increased in the postoperative period. There were no differences between the high and low pressure procedure. Elevated urinary α-1-MGB suggests kidney damage after donor nephrectomy, occurring irrespective of IAP during the laparoscopic procedure. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Transplant International 01/2015; · 3.16 Impact Factor
  • Rutger J Maas, Jeroen K Deegens, Jack F Wetzels
    [Show abstract] [Hide abstract]
    ABSTRACT: The term idiopathic nephrotic syndrome (iNS) traditionally covers minimal change disease and primary focal segmental glomerulosclerosis (FSGS), now thought to be separate disease entities. Clinical and experimental evidence suggest that circulating permeability factors are involved in their pathogenesis. In the past four decades, many investigators have searched for the responsible factors, thus far with little success. The recent report of the soluble urokinase plasminogen activator receptor as a causative factor in FSGS has received much attention, but again the initially promising findings were not confirmed. We describe the history of the search for permeability factors, discuss the pitfalls that are likely responsible for the lack of success and propose criteria that should be used in future studies when evaluating candidate permeability factors. © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
    Nephrology Dialysis Transplantation 12/2014; 29(12):2207-2216. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & AimSeveral trials have demonstrated that somatostatin analogues decrease liver volume in mixed populations of patients with autosomal dominant polycystic kidney disease (ADPKD) and isolated polycystic liver disease. Chronic renal dysfunction in ADPKD may affect treatment efficacy of lanreotide and possibly enhances risk for adverse events. The aim of this open-label clinical trial (RESOLVE trial) was to assess efficacy of 6 months lanreotide treatment 120 mg subcutaneously every 4 weeks in ADPKD patients with symptomatic polycystic liver disease.Methods Primary outcome was change in liver volume after 6 months, secondary outcomes were changes in kidney volume, eGFR, symptom relief and health-related quality of life (Euro-Qol5D). We excluded patients with an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2. We used the Wilcoxon signed-rank test or paired two-sided t-test to analyze within-group differences.ResultsWe included 43 ADPKD patients with polycystic liver disease (84% female, median age 50 years, mean eGFR 63 ml/min/1.73m2). Median liver volume decreased from 4,859 ml to 4,595 ml (-3.1%;p<0.001), and median kidney volume decreased from 1,023 ml to 1,012 ml (-1.7%;p=0.006). eGFR declined 3.5% after the first injection, remained stable up to study end, to decline again after lanreotide withdrawal. Lanreotide significantly relieved postprandial fullness, shortness of breath and abdominal distension. Three participants had a suspected episode of hepatic or renal cyst infection during the study.Conclusion Lanreotide reduced polycystic liver and kidney volumes and decreases symptoms in ADPKD patients. Moreover, eGFR decreased acutely after starting lanreotide, stabilized thereafter and declined again after withdrawal.This article is protected by copyright. All rights reserved.
    Liver international: official journal of the International Association for the Study of the Liver 11/2014; · 4.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In rodents, parietal epithelial cells (PECs) migrating onto the glomerular tuft participate in the formation of focal segmental glomerulosclerosis (FSGS) lesions. We investigated whether immunohistologic detection of PEC markers in the initial biopsies of human patients with first manifestation of idiopathic nephrotic syndrome with no immune complexes can improve the sensitivity to detect sclerotic lesions compared with standard methods. Ninety-five renal biopsies were stained for claudin-1 (PEC marker), CD44 (activated PECs), and LKIV69 (PEC matrix); 38 had been diagnosed as early primary FSGS and 57 as minimal change disease. PEC markers were detected on the tuft in 87% of the biopsies of patients diagnosed as primary FSGS. PEC markers were detected in FSGS lesions from the earliest stages of disease. In minimal change disease, no PEC activation was observed by immunohistology. However, in 25% of biopsies originally diagnosed as minimal change disease the presence of small lesions indicative of a sclerosing process were detected, which were undetectable on standard periodic acid-Schiff staining, even though only a single histologic section for each PEC marker was evaluated. Staining for LKIV69 detected lesions with the highest sensitivity. Two novel PEC markers A-kinase anchor protein 12 and annexin A3 exhibited similar sensitivity. In summary, detection of PECs on the glomerular tuft by immunostaining improves the differentiation between minimal change disease and primary FSGS and may serve to guide clinical decision making.
    American Journal Of Pathology 10/2014; · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The haemolytic uraemic syndrome (HUS) is part of a spectrum of thrombotic microangiopathies. The most common etiologies of HUS are the ones seen in childhood caused by an infection of Shiga toxin-producing Escherichia coli, HUS caused by an infection with Streptococcus pneumoniae and HUS due to abnormalities in the alternative pathway of the complement system. In the past decade, enormous progress has been made in understanding the pathogenesis in the latter group of patients. The analysis of genes that encode for complement regulatory proteins and the development of assays for measuring the activity of ADAMTS13 and the detection of antibodies against factor H contributed significantly to the diagnostic tools in patients with HUS. These assays have made it possible to clearly differentiate between thrombotic thrombocytopenic purpura and various forms of HUS. With the introduction of eculizumab, a monoclonal anti-C5 inhibitor, in the clinical arena as effective treatment of most complement-mediated forms of HUS, a new era of treatment in HUS has begun. We review the recent advances in HUS, with the focus on treatment. We discuss unsolved questions, which should be addressed in future studies.
    Nephrology Dialysis Transplantation 09/2014; 29(suppl 4):iv131-iv141. · 3.49 Impact Factor
  • Jeroen Deegens, Jack Wetzels
    Nature Reviews Nephrology 08/2014; · 7.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The optimal timing and duration of immunosuppressive therapy for idiopathic membranous nephropathy (iMN) have been debated. This study aimed to evaluate whether measuring the antibody against the phospholipase A2 receptor (PLA2R-ab) at start and end of therapy predicts long-term outcome and therefore may inform this debate.DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This observational study included all consecutive high-risk patients with progressive iMN observed from 1997 to 2005 and treated with oral cyclophosphamide (CP) or mycophenolate mofetil (MMF) in combination with corticosteroids for 12 months. Patients were prospectively followed, and outcome was ascertained up to 5 years after completion of immunosuppressive therapy. Serum samples were collected before and after completion of therapy. PLA2R antibodies were determined retrospectively in stored samples using ELISA.RESULTS: In total, 48 patients (37 men) were included. The median age was 55 years (range, 34-75), and the median serum creatinine level was 1.60 mg/dl (range, 0.98-3.37 mg/dl). Twenty-two patients received MMF and 26 received CP. At baseline, PLA2R-abs were present in 34 patients (71%). Baseline characteristics and outcome did not significantly differ between patients negative or positive for PLA2R-ab. In PLA2R-ab-positive patients, treatment resulted in a rapid decrease of antibodies: median anti-PLA2R-ab, 428 U/ml (range, 41-16,260 U/ml) at baseline and 24 U/ml (range, 0-505 U/ml) after 2 months. The PLA2R-ab levels at baseline did not predict initial response, but antibody status at end of therapy predicted long-term outcome: After 5 years, 14 of 24 (58%) antibody-negative patients were in persistent remission compared with 0 of 9 (0%) antibody-positive patients (P=0.003).CONCLUSIONS: These data suggest that in PLA2R-ab-positive patients, measuring PLA2R-abs at the end of therapy predicts the subsequent course.
    Clinical Journal of the American Society of Nephrology 07/2014; · 5.25 Impact Factor
  • Jeroen K Deegens, Jack F Wetzels
    Nature Reviews Nephrology 06/2014; · 8.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated.DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who attended the clinic were included prospectively from 1995 on. A crude incidence ratio for the occurrence of malignancy was calculated. Incidence ratios were subsequently standardized to potential confounders. Latency between cyclophosphamide therapy and the occurrence of cancer was estimated by stratifying for time since the start of treatment. Finally, Poisson regression was used to obtain a multiple adjusted incidence ratio and investigate the dose-response relationship between cyclophosphamide and cancer.RESULTS: Data were available for 272 patients; the mean age was 51 years, and 70% of the patients were men. Median follow-up was 6.0 years (interquartile range=3.6-9.5), and 127 patients were treated with cyclophosphamide. Cancer incidence was 21.2 per 1000 person-years in treated patients compared with 4.6 per 1000 person-years in patients who did not receive cyclophosphamide, resulting in crude and adjusted incidence ratios of 4.6 (95% confidence interval, 1.5 to 18.8) and 3.2 (95% confidence interval, 1.0 to 9.5), respectively.CONCLUSION: Cyclophosphamide therapy in idiopathic membranous nephropathy gives a threefold increase in cancer risk. For the average patient, this finding translates into an increase in annual risk from approximately 0.3% to 1.0%. The increased risk of malignancy must be balanced against the improved renal survival.
    Clinical journal of the American Society of Nephrology : CJASN. 05/2014;
  • Source
    05/2014; 29 Suppl 3:iii90-iii101.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Achtergrond In de eerste lijn komt chronische nierschade onder patiënten met diabetes of hypertensie veel voor. Deze cardiovasculaire risicofactor wordt echter vaak onvoldoende aangepakt. Een samenwerkingsmodel waarin huisartsen en praktijkondersteuners via internet een nefroloog kunnen consulteren, zou dat kunnen verbeteren. Methode Wij voerden een cluster-RCT uit in negen huisartsenpraktijken, onder patiënten met diabetes of hypertensie en chronische nierschade (geschatte glomerulaire filtratiesnelheid < 60ml/min/1,73 m2), Vijf praktijken pasten een jaar lang het samenwerkingsmodel toe en vier praktijken leverden reguliere zorg. Onze belangrijkste uitkomstmaten waren de gemiddelde bloeddrukverlaging en het percentage deelnemers dat de streefbloeddruk (≤ 130/80 mmHg) bereikte. Resultaten Wij analyseerden de gegevens van 90 patiënten in de interventiegroep en 74 in de controlegroep. De kans dat een patiënt een systolische bloeddruk van 130 mmHg bereikte, was in de interventiegroep 2,9 keer zo groot als in de controlegroep (95%-BI 1,4 tot 5,8), de kans op een diastolische bloeddruk van 90 mmHg was 2,5 keer zo groot (95%-BI 1,3 tot 4,7). In de interventiegroep nam de systolische bloeddruk af met 8,1 mmHg (95%-BI 4,8 tot 11,3), de diastolische met 1,1 mmHg (95%-BI –1,0 tot 3,2), tegenover –0,2 mmHg (95%-BI –3,8 tot 3,3) respectievelijk –0,5 mmHg (95%-BI –2,9 tot 1,8) in de controlegroep. In de interventiegroep lag bovendien het gebruik van lipidenverlagende middelen, RAS-remmers en vitamine D hoger en waren de concentraties parathormoon lager. Conclusie Een samenwerkingsmodel waarin huisarts, praktijkondersteuner en nefroloog samenwerken in de begeleiding van patiënten met diabetes of hypertensie en chronische nierschade, leidt tot een significant lagere systolische bloeddruk dan reguliere zorg.
    Huisarts en wetenschap 05/2014; 57(5):232-235.
  • Source
    Nephrology Dialysis Transplantation 05/2014; 29 Suppl 3:iii79-iii89. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the increasing use of pre- and posthydration protocols and low-osmolar instead of high-osmolar iodine-containing contrast media, the incidence of contrast-induced nephropathy (CIN) is still significant. There is evidence that contrast media cause ischemia-reperfusion injury of the medulla. Remote ischemic preconditioning (RIPC) is a non-invasive, safe, and low-cost method to reduce ischemia-reperfusion injury. The RIPCIN study is a multicenter, single-blinded, randomized controlled trial in which 76 patients at risk of CIN will receive standard hydration combined with RIPC or hydration with sham preconditioning. RIPC will be applied by four cycles of 5 min ischemia and 5 min reperfusion of the forearm by inflating a blood pressure cuff at 50 mmHg above the actual systolic pressure. The primary outcome measure will be the change in serum creatinine from baseline to 48 to 72 h after contrast administration. A recent pilot study reported that RIPC reduced the incidence of CIN after coronary angioplasty. The unusual high incidence of CIN in this study is of concern and limits its generalizability. Therefore, we propose a randomized controlled trial to study whether RIPC reduces contrast-induced kidney injury in patients at risk for CIN according to the Dutch guidelines.Trial registration: Current Controlled Trials ISRCTN76496973.
    Trials 04/2014; 15(1):119. · 2.12 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Slit diaphragm and podocyte damage is crucial in proteinuria pathogenesis in diabetic nephropathy (DNP). Gain-of-function mutations in TRPC6, a slit diaphragm-associated ion channel, cause glomerulosclerosis; TRPC6 expression is increased in acquired glomerular disease. Hyperglycemia and high intrarenal angiotensin II (AngII) levels could contribute to podocyte injury in DNP. We determined whether glucose regulates TRPC6 expression and TRPC6-mediated Ca(2+) influx into the podocyte and whether these effects are AngII dependent. High glucose levels increased TRPC6 mRNA and protein expression in cultured podocytes; however, TRPC1 and TRPC5 mRNA expression was unaltered. AngII and induced podocyte injury also specifically increased TRPC6 expression. Angiotensin receptor blockade and inhibition of local AngII production through angiotensin-converting enzyme inhibition prevented glucose-mediated increased TRPC6 expression. In addition, high glucose concentration pretreatment enhanced Ca(2+) influx in podocytes, which was prevented by concomitant angiotensin receptor blockade application and TRPC6 knockdown. Studies with a TRPC6 luciferase promoter construct demonstrated a glucose concentration-dependent effect on TRPC6 promoter activity. In vivo, podocyte TRPC6 protein expression was increased in proteinuric streptozotocin-induced diabetic rats. These data suggest that glucose can activate a local renin-angiotensin system in the podocyte, leading to increased TRPC6 expression, which enhances TRPC6-mediated Ca(2+) influx. Regulation of TRPC6 expression could be an important factor in podocyte injury due to chronic hyperglycemia and the antiproteinuric effect of angiotensin receptor blockade or angiotensin-converting enzyme inhibition in DNP.
    American Journal Of Pathology 04/2014; · 4.60 Impact Factor
  • Julia M Hofstra, Jack F M Wetzels
    Journal of the American Society of Nephrology 03/2014; · 9.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Membranous nephropathy, focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD) are the most common causes of idiopathic nephrotic syndrome. For many years prednisone, alkylating agents, and calcineurin inhibitors have been the standard of therapy for these patients. More effective or better tolerated treatment modalities are needed. B cell targeted therapy was recently introduced in clinical practice. In this review, we briefly summarize the current standard therapy and discuss the efficacy of B cell targeted therapy in primary glomerular diseases. Observational, short-term studies suggest that rituximab is effective and comparable to standard therapy in maintaining remissions in patients with frequently relapsing or steroid-dependent MCD or FSGS. In contrast, response is limited in patients with steroid-resistant nephrotic syndrome. Rituximab also induces remissions in patients with membranous nephropathy. Controlled clinical trials on kidney endpoints are urgently needed to position B cell targeted therapy in clinical practice.
    Advances in chronic kidney disease 03/2014; 21(2):166-181. · 2.42 Impact Factor
  • Rutger J H Maas, Jack F M Wetzels, Jeroen K J Deegens
    Kidney International 03/2014; 85(3):711. · 8.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Promising renal replacement therapies include the development of a bio-artificial kidney using functional human kidney cell models. In this study, human conditionally immortalized proximal tubular epithelial cell (ciPTEC) lines originating from kidney tissue (ciPTEC-T1 and ciPTEC-T2) were compared to ciPTEC previously isolated from urine (ciPTEC-U). Subclones of all ciPTEC isolates formed tight cell layers on Transwell inserts as determined by transepithelial resistance, inulin diffusion, E-cadherin expression and immunocytochemisty. Extracellular matrix genes collagen I and -IV α1 were highly present in both kidney tissue derived matured cell lines (p<0.001) compared to matured ciPTEC-U, whereas matured ciPTEC-U showed a more pronounced fibronectin I and laminin 5 gene expression (p<0.01 and p<0.05, respectively). Expression of the influx carrier Organic Cation Transporter 2 (OCT-2), and the efflux pumps P-glycoprotein (P-gp), Multidrug Resistance Protein 4 (MRP4) and Breast Cancer Resistance Protein (BCRP) were confirmed in the three cell lines using real-time PCR and Western blotting. The activities of OCT-2 and P-gp were sensitive to specific inhibition in all models (p<0.001). The highest activity of MRP4 and BCRP was demonstrated in ciPTEC-U (p<0.05). Finally, active albumin reabsorption was highest in ciPTEC-T2 (p<0.001), while Na(+)-dependent phosphate reabsorption was most abundant in ciPTEC-U (p<0.01). In conclusion, ciPTEC established from human urine or kidney tissue display comparable functional PTEC specific transporters and physiological characteristics, providing ideal human tools for bioartificial kidney development.
    Experimental Cell Research 02/2014; · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The soluble urokinase receptor (suPAR) promotes proteinuria and induces focal segmental glomerulosclerosis (FSGS)-like lesions in mice. A serum suPAR concentration cutoff of 3000 pg/ml has been proposed as a clinical biomarker for patients with FSGS. Interestingly, several studies in patients with glomerulopathy found an inverse correlation between the estimated glomerular filtration rate (eGFR) and suPAR. As patients with FSGS present at different eGFRs, we studied the relationship between eGFR and suPAR in a cohort of 476 non-FSGS patients and 54 patients with biopsy-proven idiopathic FSGS. In the non-FSGS patients, eGFR was the strongest significant determinant of suPAR. The proposed cutoff for suPAR in FSGS patients was exceeded in 17%, 39%, and 88% in patients with eGFRs of more than 60, 45-60, and 30-45 ml/min per 1.73 m(2), respectively. In patients with eGFR of <30 ml/min per 1.73 m(2), suPAR exceeded the cutoff in 95% of patients. Levels of suPAR in patients with idiopathic FSGS overlapped with non-FSGS controls and for any given eGFR did not discriminate FSGS cases from non-FSGS controls. In the overall cohort, there was a negative association between idiopathic FSGS and suPAR, and idiopathic FSGS was not an independent predictor of FSGS concentration over 3000 pg/ml. Thus, this study does not support an absolute, eGFR-independent, suPAR concentration cutoff as a biomarker for underlying FSGS pathology and questions the validity of relative, eGFR-dependent suPAR cutoff values.Kidney International advance online publication, 8 January 2014; doi:10.1038/ki.2013.505.
    Kidney International 01/2014; · 8.52 Impact Factor

Publication Stats

6k Citations
2,021.23 Total Impact Points


  • 1985–2014
    • Radboud University Medical Centre (Radboudumc)
      • Department of Human Genetics
      Nymegen, Gelderland, Netherlands
  • 2013
    • VU University Medical Center
      • Department of Nephrology
      Amsterdamo, North Holland, Netherlands
    • Mayo Clinic - Rochester
      Рочестер, Minnesota, United States
  • 2012
    • RWTH Aachen University
      • Nephrology and Clinical Immunology (Internal Medicine II)
      Aachen, North Rhine-Westphalia, Germany
    • Oxford University Hospitals NHS Trust
      • Department of Radiology
      Oxford, ENG, United Kingdom
  • 2011
    • Canisius-Wilhelmina Ziekenhuis
      Nymegen, Gelderland, Netherlands
  • 2009–2011
    • University Hospital RWTH Aachen
      • Division of Internal Medicine
      Aachen, North Rhine-Westphalia, Germany
  • 2006–2011
    • University Medical Center Utrecht
      • Department of Nephrology
      Utrecht, Provincie Utrecht, Netherlands
    • Amphia Ziekenhui
      Breda, North Brabant, Netherlands
  • 1987–2011
    • Radboud University Nijmegen
      • • Department of Nephrology
      • • Department of Clinical Chemistry
      • • Department of Pathology
      • • Department of Physiology
      • • Department of General Internal Medicine
      Nijmegen, Provincie Gelderland, Netherlands
  • 2008
    • Slingeland Ziekenhuis
      Doetinchem, Gelderland, Netherlands
  • 2007
    • Universitair Medisch Centrum Groningen
      • Department of Internal Medicine
      Groningen, Groningen, Netherlands
  • 2003
    • Gelderse Vallei Hospital
      • Department of Internal Medicine
      Ede, Gelderland, Netherlands
  • 1991–1994
    • University of Colorado Hospital
      • Department of Medicine
      Denver, Colorado, United States